Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02202499 · ClinicalTrials.gov registry record · Early Phase 1
Translating Extinction Research to Improve Pharmacotherapy for Tobacco Dependence
A Early Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 86
- Enrollment target
NCT02202499: Completed Early Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT02202499 is a Early Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 86 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (62% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02202499, a Early Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
The purpose of this Pilot feasibility study is to find out the effect of different behavioral treatments along with different duration of a drug called varenicline, on smoking behavior and quitting smoking. Varenicline, also known as Chantix™, is an FDA-approved medication that has been shown to help people quit smoking.
Primary Outcome
Practicality: Number of participants completing 3 month post treatment follow-up. Feasibility: Ability to recruit and retain sufficient numbers of the target population, which would be essential in conducting a future randomized clinical trial (RCT).
Interventions
- DRUG Varenicline
- OTHER Counseling and Support Materials
- OTHER Laboratory Assessments
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2014-07-17 |
| Est. Completion | 2019-06-14 |
| Phase | Early Phase 1 |
What the finished NCT02202499 record still lists
NCT02202499 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (62% higher).
The record links to 0 conditions, and to 3 interventions - of which Varenicline is the first listed.
NCT02202499 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02202499 about?
NCT02202499 is a clinical study titled "Translating Extinction Research to Improve Pharmacotherapy for Tobacco Dependence". The purpose of this Pilot feasibility study is to find out the effect of different behavioral treatments along with different duration of a drug called varenicline, on smoking behavior and quitting smoking. Varenicline, also known as Chantix™, is an FDA-approved medication that has been shown to hel...
What is the current status of trial NCT02202499?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 86 participants. The study started on 2014-07-17. Estimated completion is 2019-06-14.
What interventions are being tested in trial NCT02202499?
The interventions under investigation include: Varenicline (DRUG), Counseling and Support Materials (OTHER), Laboratory Assessments (OTHER).
Who is sponsoring clinical trial NCT02202499?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02202499's enrollment target sits among peer trials
86 256th of 2000 higher than 1,741 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI